Skip to main content

Table 1 Basic clinical and biochemical data for the patients

From: Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease

Parameters

Control (n = 23)

Lpa group (n = 23)

Original disease distribution (n)

 Chronic glomerulonephritis

14

16

 Diabetic nephropathy

5

5

 Nephrotic syndrome

0

1

 Obstructive nephropathy

1

1

 Hypertension

1

0

 Lupus nephropathy

1

0

 Polycystic kidney

1

0

Previous cardiovascular disease/events(n)

5/1

5/3

Sex (n)

 Female

11

7

 Male

12

16

Age(y)

55.4±12.2

51.7±13.4

Weight(kg)

61.0±12.1

61.8±10.4

BMI(kg/m2)

22.2±2.9

22.2±2.3

Scr (μmol/L)

665 (543,823.2)

858 (694.2,1216.1)

WC(cm)

76.5±7.9

78.5±7.6

CRP(mg/L)

5.1(1.6,8.0)

4.8(2.7,12.1)

ESR(ml/h)

52.0±34.1

67.6±32.9

Hb(g/L)

76.3±15.6

78.0±16.6

RBC(× 1012/L)

2.66±0.54

2.74±0.51

TP(g/L)

62.6±8.2

58.9±10.2

ALB(g/L)

37.5±6.6

31.8±7.2

ALT(U/L)

14.73±7.19

14.01±8.61

AST(U/L)

19.3±1.6

19.15±1.35

TG (mmol/L)

1.61(0.86,2.69)

1.21(0.90,1.59)

T-CHO(mmol/L)

3.90±0.65

4.01±0.59

LDL (mmol/L)

1.94(1.85,2.08)

2.16(1.9,2.36)

HDL (mmol/L)

1.03(0.73,1.21)

0.99(0.92,1.15)

ApoA (mmol/L)

1.13(0.97,1.2)

1.14(1.01,1.35)

ApoB (mmol/L)

0.73±0.2

0.83±0.22

Ca(mmol/L)

2.13±0.25

1.99±0.27

P(mmol/L)

1.79±0.61

1.93±0.56

Ca×P(mmol2/L2)

47.79±15.74

48.31±15.51

iPTH (ng/L)

301.2(148.1373.4

273.2(130.4553.6)

  1. There was no difference compared every index in the inflamed group with that in the control, P > 0.05